LIPO 반도체 회로 부품 판매점
Lipofectamine 2000
|
|
 ETC |
Lipofectamine™ 2000
Cat. No. 11668-027
Cat. No. 11668-019
Size: 0.75 ml
Size: 1.5 ml
Contents and Storage
Lipofectamine™ 2000 is supplied in liquid form at a concentration of 1 mg/ml. Store at +4°C. DO NOT FREEZE. Product is
guaranteed for 6 months from the date of shipment if stored properly.
Description
Lipofectamine™ 2000 is a proprietary formulation suitable for the transfection of nucleic acids into eukaryotic cells. Using
Lipofectamine™ 2000 for transfection provides the following advantages:
• The highest transfection efficiency in many cell types and formats (e.g. 96-well). Refer to the Transfection Collection and the
Invitrogen Transfection Guide available at www.invitrogen.com for a list of cell lines and cell types that have been
successfully transfected. Detailed transfection procedures are also available. For a procedure to transfect mammalian cells
with short interfering RNAs (siRNA) for use in RNA interference (RNAi) studies, see www.invitrogen.com\rnai.
• DNA-Lipofectamine™ 2000 complexes can be added directly to cells in culture medium (in the presence or absence of
serum).
• It is not necessary to remove complexes or change or add medium following transfection, although complexes can be
removed after 4-6 hours without loss of activity.
Product Qualification
Lipofectamine™ 2000 is tested for the absence of microbial contamination using blood agar plates, Sabaraud dextrose agar plates,
and fluid thioglycolate medium, and functionally by transfection of CHO-K1 cells with a luciferase reporter-containing plasmid.
Important Guidelines
Follow these guidelines when performing transfections:
1. The ratio of DNA (in µg):Lipofectamine™ 2000 (in µl) to use when preparing complexes should be 1:2 to 1:3 for most cell
lines. Some optimization may be necessary. Example: To transfect 0.5-2 x 105 cells in a 24-well format, use 0.8-1 µg DNA
and 2-3 µl of Lipofectamine™ 2000.
2. Transfect cells at high cell density. 90-95% confluence at the time of transfection is recommended to obtain high efficiency
and expression levels, and to minimize decreased cell growth associated with high transfection activity. Lower cell densities
are suitable with optimization of conditions. Take care to maintain a standard seeding protocol between experi-ments
because transfection efficiency is sensitive to culture confluence.
3. Do not add antibiotics to media during transfection as this will cause cell death.
For optimal results, we also recommend the following:
1. Use Opti-MEM® I Reduced Serum Medium (Catalog no. 31985-062) to dilute Lipofectamine™ 2000 prior to complexing with
DNA. Other media without serum (e.g. D-MEM) may be used to dilute Lipofectamine™ 2000, but transfection efficiency may
be compromised.
2. Test serum-free media formulations for compatibility with Lipofectamine™ 2000 as some serum-free formulations can
inhibit cationic lipid-mediated transfection. CD 293, 293 SFM II, and VP-SFM are media formulations known to inhibit
transfection.
Limited Use Label License No. 27
The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer
(whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components
to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes. The buyer may transfer information or
materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) to not
transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes. Commercial Purposes means any
activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a
service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such
product or its components are resold for use in research. Use of this product in conjunction with methods for the introduction of RNA molecules into cells may require licenses to one or more
patents or patent applications. Users of these products should determine if any licenses are required. Invitrogen Corporation will not assert a claim against the buyer of infringement of patents
owned by Invitrogen and claiming this product based upon the manufacture, use or sale of a therapeutic, clinical diagnostic, vaccine or prophylactic product developed in research by the buyer
in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. If the purchaser is not
willing to accept the limitations of this limited use statement, Invitrogen is willing to accept return of the product with a full refund. For information on purchasing a license to this product for
purposes other than research, contact Licensing Department, Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008. Phone (760) 603-7200. Fax (760) 602-6500.
25-0489B
Doc. Rev. 102202
Page 2
Transfection Procedure
Use the following procedure to transfect mammalian cells in a 24-well format. To transfect cells in other formats, see Scaling
Up or Down Transfections.
1. Adherent cells: One day before transfection, plate 0.5-2 x 105 cells in 500 µl of growth medium without antibiotics per
well so that they will be 90-95% confluent at the time of transfection.
Suspension cells: On the day of transfection just prior to preparing complexes, plate 4-8 x 105 cells in 500 µl of growth
medium without antibiotics per well.
2. For each transfection sample, prepare DNA-Lipofectamine™ 2000 complexes as follows:
a. Dilute DNA in 50 µl of Opti-MEM® I Reduced Serum Medium without serum (or other medium without serum). Mix
gently.
b. Mix Lipofectamine™ 2000 gently before use, then dilute the appropriate amount in 50 µl of Opti-MEM® I Medium (or
other medium without serum). Mix gently and incubate for 5 minutes at room temperature. Note: Combine the
diluted Lipofectamine™ 2000 with the diluted DNA within 30 minutes. Longer incubation times may decrease
activity. If D-MEM is used as a diluent for the Lipofectamine™ 2000, mix with the diluted DNA within 5 minutes.
c. After the 5 minute incubation, combine the diluted DNA with the diluted Lipofectamine™ 2000 (total volume is
100 µl). Mix gently and incubate for 20 minutes at room temperature to allow the DNA-Lipofectamine™ 2000
complexes to form. The solution may appear cloudy, but this will not inhibit the transfection. Note: DNA-
Lipofectamine™ 2000 complexes are stable for 6 hours at room temperature.
3. Add the 100 µl of DNA-Lipofectamine™ 2000 complexes to each well containing cells and medium. Mix gently by rocking
the plate back and forth.
4. Incubate the cells at 37°C in a CO2 incubator for 24-48 hours until they are ready to assay for transgene expression. It is
not necessary to remove the complexes or change the medium; however, growth medium may be replaced after 4-6 hours
without loss of transfection activity.
5. For stable cell lines: Passage the cells at a 1:10 or higher dilution into fresh growth medium 24 hours after transfection.
Add selective medium the following day.
For suspension cells: Add PMA and/or PHA (if desired) 4 hours after adding the DNA-Lipofectamine™ 2000 complexes
to the cells. Tip: For Jurkat cells, adding PHA-L and PMA at final concentrations of 1 µg/ml and 50 ng/ml, respectively,
enhances CMV promoter activity and gene expression. For K562 cells, adding PMA alone is sufficient to enhance
promoter activity.
Scaling Up or Down Transfections
To transfect cells in different tissue culture formats, vary the amounts of Lipofectamine™ 2000, DNA, cells, and medium used
in proportion to the difference in surface area (see table). With automated, high-throughput systems, larger complexing
volumes are recommended for transfections in 96-well plates. Note: You may perform rapid 96-well plate transfections (plate
cells and transfect simultaneously) by adding a suspension of cells directly to complexes prepared in the plate. Prepare
complexes and add cells at twice the cell density as in the basic protocol in a 100 µl volume. Cells will adhere as usual in the
presence of DNA-Lipofectamine™ 2000 complexes.
Culture
Vessel
Surface Area
per Well (cm2)
Relative Surface Volume of Plating
DNA (µg) and
Lipofectamine™ 2000 (µl)
Area (vs. 24-well)
Medium
Dilution Volume (µl) and Dilution Volume (µl)
96-well 0.3
0.2
100 µl
0.2 µg in 25 µl
0.5 µl in 25 µl
24-well 2
1
500 µl
0.8 µg in 50 µl
2.0 µl in 50 µl
12-well 4
2
1 ml
1.6 µg in 100 µl
4.0 µl in 100 µl
35-mm 10
5
2 ml
4.0 µg in 250 µl
10 µl in 250 µl
6-well 10
5
2 ml
4.0 µg in 250 µl
10 µl in 250 µl
60-mm 20
10
5 ml
8.0 µg in 0.5 ml
20 µl in 0.5 ml
10-cm 60
30
15 ml
24 µg in 1.5 ml
60 µl in 1.5 ml
Note: Surface areas are determined from actual measurements of tissue culture vessels.
Optimizing Transfection
To obtain the highest transfection efficiency and low non-specific effects, optimize transfection conditions by varying DNA
and Lipofectamine™ 2000 concentrations, and cell density. Make sure that cells are greater than 90% confluent and vary
DNA (µg):Lipofectamine™ 2000 (µl) ratios from 1:0.5 to 1:5.
©2000-2002 Invitrogen Corporation. All rights reserved.
|
국내 전력반도체 판매점
상호 : 아이지 인터내셔날
전화번호 : 051-319-2877
[ 홈페이지 ]
IGBT, TR 모듈, SCR, 다이오드모듈, 각종 전력 휴즈
( IYXS, Powerex, Toshiba, Fuji, Bussmann, Eaton )
전력반도체 문의 : 010-3582-2743
